[go: up one dir, main page]

TW200616610A - Methods for improving bioavailability - Google Patents

Methods for improving bioavailability

Info

Publication number
TW200616610A
TW200616610A TW094126194A TW94126194A TW200616610A TW 200616610 A TW200616610 A TW 200616610A TW 094126194 A TW094126194 A TW 094126194A TW 94126194 A TW94126194 A TW 94126194A TW 200616610 A TW200616610 A TW 200616610A
Authority
TW
Taiwan
Prior art keywords
methods
improving bioavailability
bioavailability
improving
inhibitor
Prior art date
Application number
TW094126194A
Other languages
English (en)
Inventor
Gian P Camenisch
Gerhard Gross
Isabel Ottinger
Daniel Wasmuth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200616610(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200616610A publication Critical patent/TW200616610A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW094126194A 2004-08-03 2005-08-02 Methods for improving bioavailability TW200616610A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
TW200616610A true TW200616610A (en) 2006-06-01

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094126194A TW200616610A (en) 2004-08-03 2005-08-02 Methods for improving bioavailability

Country Status (31)

Country Link
US (1) US7709532B2 (zh)
EP (2) EP2191823A1 (zh)
JP (1) JP5134366B2 (zh)
KR (1) KR20070040384A (zh)
CN (1) CN1993116B (zh)
AR (1) AR050043A1 (zh)
AT (1) ATE449601T1 (zh)
AU (1) AU2005268844B2 (zh)
BR (1) BRPI0514021A (zh)
CA (1) CA2572743C (zh)
CY (1) CY1109826T1 (zh)
DE (1) DE602005017905D1 (zh)
DK (1) DK1776099T3 (zh)
EC (1) ECSP077169A (zh)
ES (1) ES2335597T3 (zh)
HR (1) HRP20100064T1 (zh)
IL (1) IL180678A (zh)
MA (1) MA28821B1 (zh)
MX (1) MX2007001339A (zh)
MY (1) MY142180A (zh)
NO (1) NO20071142L (zh)
NZ (1) NZ552903A (zh)
PE (1) PE20060416A1 (zh)
PL (1) PL1776099T3 (zh)
PT (1) PT1776099E (zh)
RU (1) RU2404758C2 (zh)
SI (1) SI1776099T1 (zh)
TN (1) TNSN07038A1 (zh)
TW (1) TW200616610A (zh)
WO (1) WO2006013094A1 (zh)
ZA (1) ZA200610639B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
EP1927350A1 (en) * 2006-11-24 2008-06-04 Novartis AG Methods for improving bioavailability of a renin inhibitor
US20120165541A1 (en) 2009-07-31 2012-06-28 Sandoz Ag Method for the preparation of w-amino- alkaneamides and w-amino-alkanethioamides as well as intermediates of this method
WO2012010651A2 (en) 2010-07-23 2012-01-26 Sandoz Ag Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method
JP6385340B2 (ja) * 2013-04-12 2018-09-05 国立大学法人京都大学 巨核球の成熟化促進物質
WO2015035218A1 (en) * 2013-09-05 2015-03-12 Howard University Method of increasing the bioavailability of an hiv drug
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
WO1996040192A1 (en) 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ES2179523T3 (es) * 1997-08-14 2003-01-16 Aventis Pharma Inc Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados.
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
AU3808801A (en) * 2000-02-11 2001-08-20 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
WO2001092468A2 (en) * 2000-05-31 2001-12-06 Rutgers, The State University Of New Jersey Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
HUP0402451A3 (en) 2001-12-19 2008-04-28 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
PT1517682E (pt) 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
KR20070006774A (ko) 2004-03-17 2007-01-11 노파르티스 아게 치료에서 레닌 억제제의 용도

Also Published As

Publication number Publication date
BRPI0514021A (pt) 2008-05-27
TNSN07038A1 (en) 2008-06-02
US20080108703A1 (en) 2008-05-08
CA2572743C (en) 2012-12-04
CY1109826T1 (el) 2014-09-10
AR050043A1 (es) 2006-09-20
EP1776099A1 (en) 2007-04-25
MA28821B1 (fr) 2007-08-01
KR20070040384A (ko) 2007-04-16
EP2191823A1 (en) 2010-06-02
RU2404758C2 (ru) 2010-11-27
US7709532B2 (en) 2010-05-04
IL180678A0 (en) 2008-03-20
WO2006013094A1 (en) 2006-02-09
PT1776099E (pt) 2010-01-06
CN1993116B (zh) 2011-04-13
IL180678A (en) 2011-04-28
ZA200610639B (en) 2008-05-28
CA2572743A1 (en) 2006-02-09
EP1776099B1 (en) 2009-11-25
ATE449601T1 (de) 2009-12-15
NO20071142L (no) 2007-04-26
SI1776099T1 (sl) 2010-03-31
HRP20100064T1 (hr) 2010-03-31
AU2005268844A1 (en) 2006-02-09
MY142180A (en) 2010-10-15
JP2008508340A (ja) 2008-03-21
DE602005017905D1 (de) 2010-01-07
CN1993116A (zh) 2007-07-04
DK1776099T3 (da) 2010-03-01
MX2007001339A (es) 2007-03-27
PE20060416A1 (es) 2006-06-09
NZ552903A (en) 2010-09-30
ECSP077169A (es) 2007-02-28
ES2335597T3 (es) 2010-03-30
RU2007107850A (ru) 2008-09-10
AU2005268844B2 (en) 2009-03-05
PL1776099T3 (pl) 2010-05-31
JP5134366B2 (ja) 2013-01-30

Similar Documents

Publication Publication Date Title
TNSN07038A1 (en) Methods for improving bioavailability of a renin inhibitor
IL251185A0 (en) mek inhibitors and methods of using them
WO2006004833A3 (en) Pyrrolotriazine kinase inhibitors
SG133452A1 (en) Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
TW200633980A (en) Pyridones useful as inhibitors of kinases
IS8132A (is) Pýrósóló-kínasólín afleiður, aðferð við framleiðslu þeirra og notkun sem kínasa hindrar
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2006099610A3 (en) Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
WO2006091542A3 (en) Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
MX2009005247A (es) Metodos para mejorar la biodisponibilidad de un inhibidor de renina.
MX2007009591A (es) Metodos para disposicion mejorada de farmacos.
WO2004078180A3 (en) Naaladase inhibitors for treating opioid tolerance
WO2005103679A8 (en) Method for affinity scoring of peptide/protein complexes
WO2007062862A3 (en) Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
EP1866329A4 (en) PEPTIDES FOR TRANSGLUTAMINASE INHIBITION
WO2004002486A3 (en) Ciprofloxacin hci
TH78450A (th) วิธีการสำหรับปรับปรุงการใช้ได้ทางชีววิทยา
WO2006102126A3 (en) Inhibitors of isoprenylcysteine carboxyl methyltransferase
WO2007110705A3 (en) Macrolide as inhibitors of mhc class ii
WO2007014193A3 (en) Peptidyl diacylglycerides
WO2006094134A3 (en) Kim-1 antibodies for treatment of th2-mediated conditions
WO2007092930A3 (en) Method of treatment for mycobacterium tuberculosis
UA96736C2 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2007054725A3 (en) Combination of a cdk-inhibitor and a hdac-inhibitor